154 related articles for article (PubMed ID: 25019624)
1. Long-term outcome of 114 adult JIA patients in a non-pediatric rheumatology institute in Japan.
Miyamae T; Tanaka E; Kishi T; Matsuyama T; Igarashi T; Fujikawa S; Taniguchi A; Momohara S; Yamanaka H
Mod Rheumatol; 2015 Jan; 25(1):62-6. PubMed ID: 25019624
[TBL] [Abstract][Full Text] [Related]
2. Transition to adult rheumatology care is necessary to maintain DMARD therapy in young people with juvenile idiopathic arthritis.
Luque Ramos A; Hoffmann F; Albrecht K; Klotsche J; Zink A; Minden K
Semin Arthritis Rheum; 2017 Oct; 47(2):269-275. PubMed ID: 28583690
[TBL] [Abstract][Full Text] [Related]
3. Importance of pediatric rheumatologists and transitional care for juvenile idiopathic arthritis-associated uveitis: a retrospective series of 9 cases.
Yamazaki S; Shimbo A; Akutsu Y; Takase H; Morio T; Mori M
Pediatr Rheumatol Online J; 2020 Mar; 18(1):26. PubMed ID: 32293465
[TBL] [Abstract][Full Text] [Related]
4. [Therapy of juvenile idiopathic arthritis in early adulthood with biologics: transition from pediatric to adult care].
Niewerth M; Minden K; Klotsche J; Horneff G
Z Rheumatol; 2014 Aug; 73(6):532-40. PubMed ID: 25096586
[TBL] [Abstract][Full Text] [Related]
5. Impact of Antiinflammatory Treatment on the Onset of Uveitis in Juvenile Idiopathic Arthritis: Longitudinal Analysis From a Nationwide Pediatric Rheumatology Database.
Tappeiner C; Schenck S; Niewerth M; Heiligenhaus A; Minden K; Klotsche J
Arthritis Care Res (Hoboken); 2016 Jan; 68(1):46-54. PubMed ID: 26212111
[TBL] [Abstract][Full Text] [Related]
6. Disease activity of idiopathic juvenile arthritis continues through adolescence despite the use of biologic therapies.
Vidqvist KL; Malin M; Varjolahti-Lehtinen T; Korpela MM
Rheumatology (Oxford); 2013 Nov; 52(11):1999-2003. PubMed ID: 23893666
[TBL] [Abstract][Full Text] [Related]
7. Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance.
Horton DB; Onel KB; Beukelman T; Ringold S
J Rheumatol; 2017 Mar; 44(3):352-360. PubMed ID: 28148696
[TBL] [Abstract][Full Text] [Related]
8. Later-onset rheumatoid factor negative polyarticular juvenile idiopathic arthritis (JIA): a unique patient group?
Greenwald AG; Zakerzadeh A; Laxer RM; Schneider R; Cameron B; Feldman B; Spiegel L; Tse SM; Silverman ED
Clin Exp Rheumatol; 2013; 31(4):645-52. PubMed ID: 23622111
[TBL] [Abstract][Full Text] [Related]
9. Access to pediatric rheumatology care for Juvenile Idiopathic Arthritis in the United Arab Emirates.
Khawaja K; Al-Maini M
Pediatr Rheumatol Online J; 2017 May; 15(1):41. PubMed ID: 28511684
[TBL] [Abstract][Full Text] [Related]
10. Outcome of transition phase patients with juvenile idiopathic arthritis.
Relas H; Luosujärvi R; Kosola S
Mod Rheumatol; 2018 Sep; 28(5):832-837. PubMed ID: 29251024
[TBL] [Abstract][Full Text] [Related]
11. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort.
Guzman J; Oen K; Tucker LB; Huber AM; Shiff N; Boire G; Scuccimarri R; Berard R; Tse SM; Morishita K; Stringer E; Johnson N; Levy DM; Duffy KW; Cabral DA; Rosenberg AM; Larché M; Dancey P; Petty RE; Laxer RM; Silverman E; Miettunen P; Chetaille AL; Haddad E; Houghton K; Spiegel L; Turvey SE; Schmeling H; Lang B; Ellsworth J; Ramsey S; Bruns A; Campillo S; Benseler S; Chédeville G; Schneider R; Yeung R; Duffy CM;
Ann Rheum Dis; 2015 Oct; 74(10):1854-60. PubMed ID: 24842571
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.
Mourão AF; Santos MJ; Melo Gomes JA; Martins FM; Mendonça SC; Oliveira Ramos F; Fernandes S; Salgado M; Guedes M; Carvalho S; Costa JA; Brito I; Duarte C; Furtado C; Lopes A; Rodrigues A; Sequeira G; Branco JC; Fonseca JE; Canhão H
Rheumatology (Oxford); 2016 Apr; 55(4):697-703. PubMed ID: 26672905
[TBL] [Abstract][Full Text] [Related]
13. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
[TBL] [Abstract][Full Text] [Related]
14. Proposal for juvenile idiopathic arthritis guidance on diagnosis and treatment for primary care pediatricians and nonpediatric rheumatologists (2007).
Yokota S; Mori M; Imagawa T; Takei S; Murata T; Tomiita M; Ito Y; Fujikawa S
Mod Rheumatol; 2007; 17(5):353-63. PubMed ID: 17929125
[TBL] [Abstract][Full Text] [Related]
15. Outcome and Trends in Treatment of Systemic Juvenile Idiopathic Arthritis in the German National Pediatric Rheumatologic Database, 2000-2013.
Klotsche J; Raab A; Niewerth M; Sengler C; Ganser G; Kallinich T; Niehues T; Hufnagel M; Thon A; Hospach T; Horneff G; Minden K
Arthritis Rheumatol; 2016 Dec; 68(12):3023-3034. PubMed ID: 27332999
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
[TBL] [Abstract][Full Text] [Related]
17. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
[TBL] [Abstract][Full Text] [Related]
18. Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients.
Romano M; Pontikaki I; Gattinara M; Ardoino I; Donati C; Boracchi P; Meroni PL; Gerloni V
Reumatismo; 2014 Mar; 65(6):278-85. PubMed ID: 24705031
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported Outcomes across Categories of Juvenile Idiopathic Arthritis.
Taxter AJ; Wileyto EP; Behrens EM; Weiss PF
J Rheumatol; 2015 Oct; 42(10):1914-21. PubMed ID: 26329337
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
